Who
Wouter Joustra
Director
Company insider
Files Form 4 as: Director, enGene Therapeutics; Director, Vor Biopharma.
In numbers
- Trades disclosed
- 7
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 15 Jun 2024
- Last trade
- 16 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | VOR Vor Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —57,162 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | VOR Vor Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —57,162 at $0.00 | filing |
| 18 Dec 2025filed 19 Dec 2025 | VOR Vor Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 16 Jun 2025filed 16 Jun 2025 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 15 Jun 2024filed 18 Jun 2024 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.